Sign in

ABBOTT LABORATORIES

ABT· NYSE· Pharmaceutical Preparations

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
16.7%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
+5.1%
We record prices for the companies we cover; ABT is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
1.75B
Revenue
$44.3B
Free cash flow
$7.4B
Owner earnings
$6.7B

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
–
Operating
18.2%
Net
14.7%
Free cash flow
16.7%
Owner earnings
15.2%
Stock pay
1.5%

Returns

ROIC, FY2025
11.1%
ROIC, 5 yr avg
–
ROE, FY2025
12.5%
ROE, 5 yr avg
18.8%

Growth (CAGR)

Revenue, 3 yr
0.5%
Revenue, 5 yr
5.1%
Revenue, 9 yr
8.7%
Diluted EPS, 3 yr
-1.6%
Diluted EPS, 5 yr
8.3%
Diluted EPS, 9 yr
16.5%
Free cash flow, 3 yr
-1.8%
Free cash flow, 5 yr
5.3%
Free cash flow, 9 yr
15.1%

Financial health · FY2025

Cash and investments
$8.9B
Total debt
$12.9B
Net debt
$4.0B
Debt/Equity
0.2x
Debt/FCF
1.7x

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
63.1%
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
-0.4%

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$44.3B

+8.7% a year over 9 years

FY2016: Revenue $20.9BFY2017: Revenue $27.4BFY2018: Revenue $30.6BFY2019: Revenue $31.9BFY2020: Revenue $34.6BFY2021: Revenue $43.1BFY2022: Revenue $43.7BFY2023: Revenue $40.1BFY2024: Revenue $42.0BFY2025: Revenue $44.3B
FY2016FY2025

Margins

Operating18.2%Net14.7%

FY2025

FY2016: Operating 14.5%, Net 6.7%FY2017: Operating 5.7%, Net 1.7%FY2018: Operating 11.9%, Net 7.7%FY2019: Operating 14.2%, Net 11.6%FY2020: Operating 15.5%, Net 13.0%FY2021: Operating 19.6%, Net 16.4%FY2022: Operating 19.2%, Net 15.9%FY2023: Operating 16.2%, Net 14.3%FY2024: Operating 16.3%, Net 31.9%FY2025: Operating 18.2%, Net 14.7%
FY2016FY2025

Free cash flow and owner earnings

Free cash flow$7.4BOwner earnings$6.7B

Free cash flow +15.1% a year

FY2016: Free cash flow $2.1B, Owner earnings $1.8BFY2017: Free cash flow $4.4B, Owner earnings $4.0BFY2018: Free cash flow $4.9B, Owner earnings $4.4BFY2019: Free cash flow $4.5B, Owner earnings $4.0BFY2020: Free cash flow $5.7B, Owner earnings $5.2BFY2021: Free cash flow $8.6B, Owner earnings $8.0BFY2022: Free cash flow $7.8B, Owner earnings $7.1BFY2023: Free cash flow $5.1B, Owner earnings $4.4BFY2024: Free cash flow $6.4B, Owner earnings $5.7BFY2025: Free cash flow $7.4B, Owner earnings $6.7B
FY2016FY2025

Diluted shares

1.75B

+17.9% over 9 years, net dilution

FY2016: Diluted shares 1.48BFY2017: Diluted shares 1.75BFY2018: Diluted shares 1.77BFY2019: Diluted shares 1.78BFY2020: Diluted shares 1.79BFY2021: Diluted shares 1.79BFY2022: Diluted shares 1.76BFY2023: Diluted shares 1.75BFY2024: Diluted shares 1.75BFY2025: Diluted shares 1.75B
FY2016FY2025

Return on invested capital

11.1%

FY2025

FY2016: ROIC 9.6%FY2017: ROIC 0.5%FY2018: ROIC 6.4%FY2019: ROIC 9.1%FY2020: ROIC 10.9%FY2021: ROIC 16.6%FY2022: ROIC 16.1%FY2023: ROIC 12.1%FY2024: ROIC –FY2025: ROIC 11.1%
FY2016FY2025

Net debt (below zero)

-$4.0B

$4.0B more debt than cash

FY2016: Net cash -$3.2BFY2017: Net cash -$18.3BFY2018: Net cash -$15.5BFY2019: Net cash -$14.0BFY2020: Net cash -$11.6BFY2021: Net cash -$7.8BFY2022: Net cash -$6.6BFY2023: Net cash -$7.4BFY2024: Net cash -$6.2BFY2025: Net cash -$4.0B
FY2016FY2025

Every figure, year by year

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
The business
Revenue$20.9B$27.4B$30.6B$31.9B$34.6B$43.1B$43.7B$40.1B$42.0B$44.3B
Revenue growth2.2%31.3%11.6%4.3%8.5%24.5%1.3%-8.1%4.6%5.7%
Gross margin––––––––––
Operating margin14.5%5.7%11.9%14.2%15.5%19.6%19.2%16.2%16.3%18.2%
Net income$1.4B$477.0M$2.4B$3.7B$4.5B$7.1B$6.9B$5.7B$13.4B$6.5B
Net margin6.7%1.7%7.7%11.6%13.0%16.4%15.9%14.3%31.9%14.7%
Diluted EPS$0.94$0.27$1.33$2.06$2.50$3.94$3.91$3.26$7.64$3.72
Return on invested capital?9.6%0.5%6.4%9.1%10.9%16.6%16.1%12.1%–11.1%
Cash
Operating cash flow$3.2B$5.6B$6.3B$6.1B$7.9B$10.5B$9.6B$7.3B$8.6B$9.6B
Capital expenditure$1.1B$1.1B$1.4B$1.6B$2.2B$1.9B$1.8B$2.2B$2.2B$2.2B
Free cash flow$2.1B$4.4B$4.9B$4.5B$5.7B$8.6B$7.8B$5.1B$6.4B$7.4B
Stock-based compensation$310.0M$406.0M$477.0M$519.0M$546.0M$640.0M$685.0M$644.0M$673.0M$664.0M
Owner earnings?$1.8B$4.0B$4.4B$4.0B$5.2B$8.0B$7.1B$4.4B$5.7B$6.7B
Free cash flow per share$1.40$2.54$2.77$2.53$3.20$4.83$4.42$2.89$3.63$4.23
Capital allocation
Dividends paid$1.5B$1.8B$2.0B$2.3B$2.6B$3.2B$3.3B$3.6B$3.8B$4.1B
Share repurchases$522.0M$117.0M$238.0M$718.0M$403.0M$2.3B$3.8B$1.2B$1.3B$893.0M
Diluted shares1.48B1.75B1.77B1.78B1.79B1.79B1.76B1.75B1.75B1.75B
Share count change?-1.5%17.9%1.2%0.6%0.3%0.2%-1.4%-0.9%-0.1%0.0%
Balance sheet
Cash and equivalents$18.6B$9.4B$3.8B$3.9B$6.8B$9.8B$9.9B$6.9B$7.6B$8.5B
Short-term investments$155.0M$203.0M$242.0M$280.0M$310.0M$450.0M$288.0M$383.0M$351.0M$417.0M
Total debt$22.0B$27.9B$19.6B$18.1B$18.7B$18.1B$16.8B$14.7B$14.1B$12.9B
Net debt$3.2B$18.3B$15.5B$14.0B$11.6B$7.8B$6.6B$7.4B$6.2B$4.0B
Shareholders' equity$20.5B$30.9B$30.5B$31.1B$32.8B$35.8B$36.7B$38.6B$47.7B$52.1B

Latest filings

All on EDGAR
2026-10-218-KEarnings release
2026-07-2810-QQuarterly report
2026-07-168-KEarnings release
2026-04-2910-QQuarterly report
2026-04-168-KEarnings release
2026-03-13DEF 14AProxy statement
2026-02-2010-KAnnual report
2026-01-228-KEarnings release
2025-10-2910-QQuarterly report
2025-10-158-KEarnings release

More from our coverage

All coverage